Kalaris Therapeutics
KLRS
94 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 10 closing their positions.
161% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 18
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
18% more capital invested
Capital invested by funds: $156M → $184M (+$27.6M)
6% more funds holding
Funds holding: 89 → 94 (+5)
0.22% more ownership
Funds ownership: 1.84% → 2.07% (+0.22%)
22% less call options, than puts
Call options by funds: $172K | Put options by funds: $221K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$22.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.89M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.22M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.18M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.16M |
| 2 |
Renaissance Technologies
New York
|
-$582K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$281K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$238K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$228K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Prudential Financial
Newark,
New Jersey
| – | -$57.9K | -639 | Closed |
|
102
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$54K | -596 | Closed |
|
103
Simplex Trading
Chicago,
Illinois
| – | -$10.2K | -107 | Closed |
|
|
QCG
104
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1.37K | -15 | Closed |
|
KLRS Hedge Fund Activity: Q2 2023 in Review
94 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2023, worth a combined $184M — up 18% from $156M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KLRS positions and 10 closed out — a net gain of 5 holders — while 47 added to existing stakes and 18 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $22.3M. The largest seller was Vanguard Group, cutting an estimated $1.16M.
- 94 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2023, up from 89 in Q1 2023.
- Funds reported $184M of Kalaris Therapeutics stock for Q2 2023, up 18% quarter-over-quarter.
- 15 funds opened new Kalaris Therapeutics positions in Q2 2023 and 10 closed out, a net change of +5 holders.
- The largest Kalaris Therapeutics buyer in Q2 2023 was Wasatch Advisors, an estimated $22.3M added.
- The largest Kalaris Therapeutics seller in Q2 2023 was Vanguard Group, an estimated $1.16M sold.
Based on aggregated 13F filings for Q2 2023.